SOMERSET, N.J., Feb. 14 /PRNewswire-FirstCall/ -- Ventiv Pharma Services, LLC, a division of Ventiv Health, Inc. , announced today that it has signed an agreement with Bayer HealthCare LLC, Diabetes Care Division, a member of the Bayer Group . Under the terms of the agreement, Ventiv Pharma Services(TM) will deploy a team of sales representatives to promote Bayer's complete range of Ascensia(R) diabetes care products and services to retail pharmacists, strengthening Ventiv's service offering in this product category.
Ascensia means to 'ascend and achieve.' The complete range of Ascensia diabetes care products and services are designed to help patients do just that -- rise above their disease to experience life's many possibilities. This unique approach is called "Your Life. Your Way." and reflects Bayer HealthCare's dedication to the principle that Ascensia products and services will help people define their lives in terms of their goals and achievements -- not their diabetes. Ascensia represents Bayer's evolution towards self-directed patient care, as the company has been a leader in diabetes monitoring and management since 1941.
"Pharmacists play a pivotal role in the lives of people with diabetes, and often are a person's most local or most trusted source of health information," said David Argento, Director, National Accounts for Bayer HealthCare's Diabetes Care Division. "By teaming with Ventiv, Bayer believes it can achieve one of its primary goals of supporting these health professionals in a way that has a meaningful impact on the lives of their patients."
Ventiv Pharma Service's broad product portfolio of experience includes pharmaceuticals, medical devices, over the counter products, diagnostics and medical services. VPS has built over 63 teams in the past five years, targeted 50 different practitioner specialties, and promoted products across multiple therapeutics categories.
Terrell Herring, President and COO, Ventiv Pharma Services(TM), said, "We have worked with Bayer over the past several years, and are very pleased to be able to provide our services to another Bayer HealthCare division. This decision underscores Bayer's continued confidence in Ventiv's ability to deliver positive results with their diagnostic product line."
About Ventiv Health
Ventiv Health, Inc. is the leading provider of late-stage clinical, sales, marketing and compliance solutions to pharmaceutical and biotech companies. Ventiv is a multi-disciplinary company with a singular focus on providing excellence in customized solutions across the full spectrum of services combining both integrated and independent programs. Ventiv's approximately 4,000 employees support over 75 client organizations, including the world's Top 20 pharmaceuticals companies as well as emerging and specialty biotech leaders. For more information on Ventiv Health, visit http://www.ventiv.com/.
Bayer HealthCare Diabetes Care Division
Bayer HealthCare Diabetes Care Division is one of the largest self-test diagnostic businesses in the world, supporting customers in 100 countries. Since the introduction of Clinitest(R) reagent tablets in 1941 -- Bayer has led the way in diabetes care product innovation. The company changed the face of diabetes care in 1969 when it introduced the first portable blood glucose meter and strips. Bayer HealthCare further innovated diabetes self-management by being the first company to introduce a suite of blood glucose monitors that do not require coding. The Ascensia(R) CONTOUR(R), Ascensia(R) BREEZE(R) and Ascensia(R) DEX(R)2 systems offer people with diabetes unparalleled choice in blood glucose monitoring meters. Bayer HealthCare Diabetes Care Division's global headquarters in the United States operates as part of Bayer HealthCare LLC, a member of the worldwide Bayer HealthCare group.
Bayer HealthCare AG
Bayer HealthCare AG, a subgroup of Bayer AG with sales of approximately 8.9 billion Euro in 2003, is one of the world's leading, innovative companies in the health care and medical products industry. The company combines the global activities of the divisions Animal Health, Biological Products, Consumer Care, Diagnostics, Diabetes Care and Pharmaceuticals. More than 34,000 people are employed by Bayer HealthCare worldwide. Our aim is to discover and manufacture innovative products that will improve human and animal health worldwide. Our products enhance well-being and quality of life by diagnosing, preventing and treating disease.
This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management and forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 made by Ventiv Health, Inc. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. For Bayer Group, these factors include those discussed in our public reports filed with the Frankfurt Stock Exchange and with the U.S. Securities and Exchange Commission (including our Form 20-F). The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. For Ventiv Health Inc. such risks include, without limitation: changes in trends in the pharmaceutical industry or in pharmaceutical outsourcing; our ability to compete successfully with other services in the market; our ability to maintain large client contracts or to enter into new contracts; uncertainties related to future incentive payments; and, our ability to operate successfully in new lines of business. Readers of this press release are referred to documents filed from time to time by VentivHealth Inc. with the Securities and Exchange Commission for further discussion of these and other factors.
Ventiv Pharma Services, LLC